[1]孙 铎,张秀珍,邓晓君.不同剂量二甲双胍联合磷酸西格列汀治疗2型糖尿病患者的临床疗效及安全性观察[J].医学信息,2023,36(09):135-138.[doi:10.3969/j.issn.1006-1959.2023.09.028]
　SUN Duo,ZHANG Xiu-zhen,DENG Xiao-jun.Clinical Efficacy and Safety of Different Doses of Metformin Combined with Sitagliptin Phosphate in the Treatment of Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2023,36(09):135-138.[doi:10.3969/j.issn.1006-1959.2023.09.028]
点击复制

不同剂量二甲双胍联合磷酸西格列汀治疗2型糖尿病患者的临床疗效及安全性观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年09期
页码:
135-138
栏目:
论著
出版日期:
2023-05-01

文章信息/Info

Title:
Clinical Efficacy and Safety of Different Doses of Metformin Combined with Sitagliptin Phosphate in the Treatment of Patients with Type 2 Diabetes Mellitus
文章编号:
1006-1959（2023）09-0135-04
作者:
孙 铎; 张秀珍; 邓晓君
（佳木斯市中心医院内分泌科，黑龙江 佳木斯 154002）
Author(s):
SUN Duo; ZHANG Xiu-zhen; DENG Xiao-jun
(Department of Endocrinology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
2型糖尿病; 二甲双胍; 磷酸西格列汀; 给药剂量; 血糖指标
Keywords:
Type 2 diabetes mellitus; Metformin; Sitagliptin phosphate; Dosage; Blood glucose index
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2023.09.028
文献标志码:
A
摘要:
目的 探究不同剂量二甲双胍联合磷酸西格列汀治疗2型糖尿病（T2DM）的临床疗效及安全性。方法 选取2019年2月-2022年2月佳木斯市中心医院收治的90例T2DM病例，按照随机数字表法分为高剂量组（45例）和低剂量组（45例）。两组均采用二甲双胍联合磷酸西格列汀治疗，高剂量组二甲双胍给药剂量为0.85 g/次，2次/d；低剂量组二甲双胍给药剂量为0.50 g/次，2次/d。比较两组血糖指标[空腹血糖（FBG）、餐后2 h血糖（2hPBG）、糖化血红蛋白（HbA1c）]、胰岛功能[空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）]、血脂指标[总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）]、不良反应。结果 两组治疗后HbA1c、FPG、2hPBG低于治疗前，且高剂量组HbA1c、FPG、2hPBG低于低剂量组（P＜0.05）；高剂量组治疗后FINS高于低剂量组，HOMA-IR低于低剂量组（P＜0.05）；高剂量组治疗后TG、TC、LDL-C低于低剂量组，HDL-C高于低剂量组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 高剂量二甲双胍联合磷酸西格列汀治疗T2DM效果可观，相较于低剂量方案，其在血糖指标、胰岛功能及血脂水平的调节中具有更高优势，且安全性好。
Abstract:
Objective To explore the clinical efficacy and safety of different doses of metformin combined with sitagliptin phosphate in the treatment of type 2 diabetes mellitus (T2DM).Methods A total of 90 cases of T2DM admitted to Jiamusi Central Hospital from February 2019 to February 2022 were selected and divided into high-dose group (45 cases) and low-dose group (45 cases) according to the random number table method. Both groups were treated with metformin combined with sitagliptin phosphate. The dose of metformin in the high-dose group was 0.85 g/time, twice daily. The dose of metformin in the low-dose group was 0.50 g/time, twice daily. The blood glucose indexes [fasting blood glucose (FBG), 2 h postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c)], islet function [ fasting insulin (FINS), insulin resistance index (HOMA-IR)], blood lipid indexes [total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)] and adverse reactions were compared between the two groups.Results After treatment, HbA1 c, FPG and 2hPBG in the two groups were lower than those before treatment, and HbA1c, FPG and 2hPBG in the high-dose group were lower than those in the low-dose group (P<0.05). After treatment, FINS in the high-dose group was higher than that in the low-dose group, and HOMA-IR was lower than that in the low-dose group (P<0.05). After treatment, TG, TC and LDL-C in the high-dose group were lower than those in the low-dose group, and HDL-C was higher than that in the low-dose group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion High-dose metformin combined with sitagliptin phosphate is effective in the treatment of T2DM. Compared with low-dose regimen, it has higher advantages in the regulation of blood glucose index, islet function and blood lipid level, and has good safety.

参考文献/References:

[1]常娟,谢瑾,王平,等.西格列汀联合二甲双胍治疗老年2型糖尿病患者糖脂代谢紊乱及微炎症状态的影响[J].河北医药,2022,44(2):235-238.[2]黄金华.西格列汀联合二甲双胍治疗老年2型糖尿病疗效分析[J].中华老年多器官疾病杂志,2017,16(5):358-361.[3]员婷.磷酸西格列汀联合二甲双胍对2型糖尿病患者血糖控制及胰岛素抵抗的治疗效果[J].中国医药导报,2021,18(6):91-94.[4]魏亚兰,吴玉红,胡丽格,等.磷酸西格列汀联合二甲双胍对2型糖尿病患者血糖控制及微炎性反应状态的影响[J].中国医师进修杂志,2021,44(2):128-132.[5]杨晓彦,孟振.西格列汀联合二甲双胍对糖尿病患者的有效性及不良反应发生的影响[J].中国药物与临床,2020,20(17):2893-2895.[6]王艳燕,孔艳华,张德桂,等.西格列汀与二甲双胍对新诊断2型糖尿病患者胰岛β细胞功能的影响[J].贵州医科大学学报,2020,45(3):340-344.[7]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.[8]陈红霞,史婷婷,袁群,等.西格列汀与二甲双胍联用治疗老年2型糖尿病的疗治效观察[J].微循环学杂志,2019,29(1):18-22.[9]王芬,陈开宁,郑小瑛,等.二甲双胍联合西格列汀治疗2型糖尿病的疗效观察[J].中国热带医学,2018,18(8):819-822.[10]李霞,白小岗,刘欣齐,等.单用二甲双胍血糖控制不达标的老年2型糖尿病患者联合西格列汀治疗的临床疗效及安全性分析[J].空军医学杂志,2017,33(6):384-387.[11]杨卫东.二甲双胍联合西格列汀对初诊T2DM患者临床疗效分析[J].药物评价研究,2018,41(4):643-647.[12]敬仁芝,曹晓红.磷酸西格列汀联合阿卡波糖对老年2型糖尿病患者血糖、血脂及GLUT4水平的影响[J].中国药房,2017,28(9):1204-1207.[13]肖康,冯其乡.二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征疗效评价[J].中国药业,2018,27(7):47-49.[14]吴晓丽,陈大双,张悦玲.西格列汀二甲双胍片(Ⅱ)治疗2型糖尿病的临床研究[J].现代药物与临床,2018,33(2):346-350.[15]刘阳,杨静,任毅,等.磷酸西格列汀联合二甲双胍治疗2型糖尿病的临床疗效观察[J].中西医结合心脑血管病杂志,2018,16(12):1725-1727.[16]干异,杨成会.西格列汀联合二甲双胍对2型糖尿病患者糖、脂代谢及胰岛素抵抗的影响[J].中国煤炭工业医学杂志,2017,20(12):1442-1446.[17]黄好武,周春仲,曾满凤.西格列汀与二甲双胍联合治疗2型糖尿病的疗效观察[J].中国医院用药评价与分析,2017,17(7):914-915,918.[18]李少卿,刘湛一.二甲双胍对肥胖2型糖尿病患者血糖水平及胰岛素抵抗的作用[J].中国医药科学,2017,7(2):64-66.[19]Zhou L,Liu H,Wen X,et al.Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials[J].J Hypertens,2017,35(1):18-26.[20]周焰,韩亮.磷酸西格列汀联合二甲双胍治疗初发型2型糖尿病患者的疗效[J].安徽医学,2017,38(4):476-478.[21]姚璐,张薇,武云涛,等.磷酸西格列汀联合不同剂量二甲双胍治疗2型糖尿病的临床疗效观察[J].中国循证心血管医学杂志,2015,7(6):807-808,811.[22]Rowan JA,Rush EC,Plank LD,et al.Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age[J].BMJ Open Diabetes Res Care,2018,6(1):e000456.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(09):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(09):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(09):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(09):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(09):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[8]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(09):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[9]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(09):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[10]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(09):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[11]刘朝阳,张善革.二甲双胍单药及不同联合用药方案治疗2型糖尿病的随机对照研究[J].医学信息,2019,32(04):148.[doi:10.3969/j.issn.1006-1959.2019.04.048]
　LIU Chao-yang,ZHANG Shan-ge.A Randomized Controlled Trial of Metformin Monotherapy and Different Combination Regimens in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2019,32(09):148.[doi:10.3969/j.issn.1006-1959.2019.04.048]
[12]金 川,张 颖,李瑞环,等.葛根芩连汤对2型糖尿病患者糖脂代谢指标及 体重的影响[J].医学信息,2019,32(14):164.[doi:10.3969/j.issn.1006-1959.2019.14.055]
　JIN Chuan,ZHANG Ying,LI Rui-huan,et al.Effect of Gegen Qinlian Decoction on Glucose and Lipid Metabolism Index and Body Weight in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2019,32(09):164.[doi:10.3969/j.issn.1006-1959.2019.14.055]
[13]尤 丽,卢 琦.甘精胰岛素联合二甲双胍治疗2型糖尿病的疗效[J].医学信息,2020,33(02):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
　YOU Li,LU Qi.Effect of Insulin Glargine Combined with Metformin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2020,33(09):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
[14]张月田,刘世平.二甲双胍治疗2型糖尿病的不良反应及联合用药的应用[J].医学信息,2021,34(06):64.[doi:10.3969/j.issn.1006-1959.2021.06.017]
　ZHANG Yue-tian,LIU Shi-ping.Adverse Reactions of Metformin in the Treatment of Type 2 Diabetes and the Application of Combined Medication[J].Journal of Medical Information,2021,34(09):64.[doi:10.3969/j.issn.1006-1959.2021.06.017]
[15]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[16]房 芳,于 宏.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观察[J].医学信息,2022,35(16):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]
　FANG Fang,YU Hong.Effect of Liraglutide Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(09):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]
[17]杨晓旭,赵振宇.亚莫利联合二甲双胍对2型糖尿病的降糖效果观察[J].医学信息,2023,36(10):134.[doi:10.3969/j.issn.1006-1959.2023.10.029]
　YANG Xiao-xu,ZHAO Zhen-yu.Observation on Hypoglycemic Effect of Amaryl Combined with Metformin on Type 2 Diabetes Mellitus[J].Journal of Medical Information,2023,36(09):134.[doi:10.3969/j.issn.1006-1959.2023.10.029]
[18]廖 萌,淦作梅.达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响[J].医学信息,2024,37(13):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
　Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type Diabetes Mellitus.Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(09):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]

更新日期/Last Update: 1900-01-01